First Patient Is Dosed With Base Editor to Treat...
Aug. 17, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Verve Therapeutics
Main focus: Gene editing for the treatment of genetic cardiovascular diseases
Company stage: Pre-clinical
Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia
Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:VERV)
Location: Cambridge, MA, USA
Website: https://www.vervetx.com/
Pipeline: https://www.vervetx.com/pipeline/
Partners: Beam Therapeutics
Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.
